SynCore Biotechnology Financials
| 4192 Stock | TWD 33.90 0.40 1.17% |
SynCore |
Understanding current and past SynCore Biotechnology Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of SynCore Biotechnology's financial statements are interrelated, with each one affecting the others. For example, an increase in SynCore Biotechnology's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in SynCore Biotechnology's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of SynCore Biotechnology Co. Check SynCore Biotechnology's Beneish M Score to see the likelihood of SynCore Biotechnology's management manipulating its earnings.
SynCore Biotechnology Stock Summary
SynCore Biotechnology competes with LongDa Construction, Wei Chuan, Hung Sheng, Da Cin, and Hi Lai. ,Ltd, a biopharmaceutical company, engages in the research and development, manufacture, and marketing of drugs in the areas of oncology, ophthalmology, dermatology, and infectious diseases in Taiwan and internationally. The company was founded in 2008 and is headquartered in Yilan, Taiwan. SYNCORE BIOTECHNOL operates under Biotechnology classification in Taiwan and is traded on Taiwan OTC Exchange. It employs 81 people.| Instrument | Taiwan Stock View All |
| Exchange | Taiwan OTC Exchange |
| ISIN | TW0004192000 |
| Business Address | 84 Chung Shan |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | www.syncorebio.com |
| Phone | 886 3 958 6101 |
| Currency | TWD - New Taiwan Dollar |
You should never invest in SynCore Biotechnology without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of SynCore Stock, because this is throwing your money away. Analyzing the key information contained in SynCore Biotechnology's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
SynCore Biotechnology Key Financial Ratios
There are many critical financial ratios that SynCore Biotechnology's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that SynCore Biotechnology reports annually and quarterly.| Return On Equity | -0.43 | |||
| Return On Asset | -0.16 | |||
| Number Of Employees | 65 | |||
| Beta | 1.14 | |||
| Z Score | 28.2 |
SynCore Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining SynCore Biotechnology's current stock value. Our valuation model uses many indicators to compare SynCore Biotechnology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across SynCore Biotechnology competition to find correlations between indicators driving SynCore Biotechnology's intrinsic value. More Info.SynCore Biotechnology Co is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the SynCore Biotechnology's earnings, one of the primary drivers of an investment's value.SynCore Biotechnology Systematic Risk
SynCore Biotechnology's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. SynCore Biotechnology volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on SynCore Biotechnology correlated with the market. If Beta is less than 0 SynCore Biotechnology generally moves in the opposite direction as compared to the market. If SynCore Biotechnology Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one SynCore Biotechnology is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of SynCore Biotechnology is generally in the same direction as the market. If Beta > 1 SynCore Biotechnology moves generally in the same direction as, but more than the movement of the benchmark.
SynCore Biotechnology Thematic Clasifications
SynCore Biotechnology Co is part of Biotech investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Biotechnology and pharmaceuticals production and services. Companies specialized in biotechnology production and delivery of pharmaceuticals services
This theme covers Biotechnology and pharmaceuticals production and services. Companies specialized in biotechnology production and delivery of pharmaceuticals services. Get More Thematic Ideas
| Biotech | View |
SynCore Biotechnology March 26, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of SynCore Biotechnology help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of SynCore Biotechnology Co. We use our internally-developed statistical techniques to arrive at the intrinsic value of SynCore Biotechnology Co based on widely used predictive technical indicators. In general, we focus on analyzing SynCore Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build SynCore Biotechnology's daily price indicators and compare them against related drivers.
| Information Ratio | (0.01) | |||
| Maximum Drawdown | 20.67 | |||
| Value At Risk | (2.40) | |||
| Potential Upside | 3.99 |
Additional Tools for SynCore Stock Analysis
When running SynCore Biotechnology's price analysis, check to measure SynCore Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SynCore Biotechnology is operating at the current time. Most of SynCore Biotechnology's value examination focuses on studying past and present price action to predict the probability of SynCore Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SynCore Biotechnology's price. Additionally, you may evaluate how the addition of SynCore Biotechnology to your portfolios can decrease your overall portfolio volatility.